FWM
REGN icon

Focused Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Focused Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-400
Closed -$385K – 257
2024
Q1 		$385K Buy
+400
New +$380K 0.06% 102
2023
Q4 		– Sell
-400
Closed -$12.4K – 1088
2023
Q3 		$12.4K Buy
+400
New +$314K ﹤0.01% 488

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Focused Wealth Management's REGN Position: Q1 2026 in Review

Focused Wealth Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 384 shares worth $297K. The stake represents 0.03% of the portfolio and ranks #157 among its holdings. This is a return to the name: Focused Wealth Management previously reported a position in REGN as recently as Q1 2024.

Focused Wealth Management first reported a position in REGN in Q4 2015 and has held it in 29 quarters since. The position peaked at $856K in Q3 2018. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Focused Wealth Management held 384 shares of Regeneron Pharmaceuticals worth $297K as of Q1 2026.
  • Regeneron Pharmaceuticals was a new Focused Wealth Management position in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.03% of Focused Wealth Management's portfolio in Q1 2026, its #157 holding.
  • Focused Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2015 and has held it in 29 quarters since.
  • Focused Wealth Management's Regeneron Pharmaceuticals position peaked at $856K in Q3 2018.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Focused Wealth Management's 13F filing for Q1 2026, filed 20 Apr 2026.